Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 10:6:5-6.
doi: 10.1016/j.eclinm.2019.01.001. eCollection 2018 Dec.

Patient-centered Care and Treatment in HIV Infection

Massimiliano Lanzafame  1 , Sandro Vento  2   3
Affiliations

Patient-centered Care and Treatment in HIV Infection

Massimiliano Lanzafame et al. EClinicalMedicine. .
No abstract available

PubMed Disclaimer

References

    1. Diaco N.D., Strickler C., Giezendanner S., Wirz S.A., Tarr P.E. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons. EClinicalMedicine. 2019 - PMC - PubMed
    1. Comi L., Di Filippo E., Maggiolo F. Dolutegravir plus lamivudine as simplification dual therapy in virologically suppressed HIV-1 infected subjects. J Immunol Sci. 2018;2(1):60–64.
    1. Smit M., Brinkman K., Geerlings S. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–818. - PMC - PubMed
    1. de-Graft Aikins A., Unwin N., Agyemang C., Allotey P., Campbell C., Arhinful D. Tackling Africa's chronic disease burden: from the local to the global. Glob Health. 2010;6:5. - PMC - PubMed
    1. Gianella S., Marconi V.C., Berzins B. Genital HIV-1 shedding with Dolutegravir (DTG) plus Lamivudine (3TC) dual therapy. J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):e112–e114. - PMC - PubMed

LinkOut - more resources